Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. AIDS Behav, 19(5), 794-801. presented at the 2015 May. doi:10.1007/s10461-014-0958-x. (2015).
Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One, 8(9), e74314. presented at the 2013. doi:10.1371/journal.pone.0074314. (2013).
Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PLoS One, 7(4), e33103. presented at the 2012. doi:10.1371/journal.pone.0033103. (2012).